Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,515.17
(
0.95%
)
US TECH 100
28,868.40
(
0.98%
)
Dow Jones
50,148.27
(
0.92%
)
Brent Oil
102.50
(
-1.15%
)
Bitcoin
81,543.52
(
2.85%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: The Other Guy post# 278953

Thursday, 11/17/2016 3:07:17 PM

Thursday, November 17, 2016 3:07:17 PM

Post# of 347009
I would think King has been very cautious in his wordings, as much as he can be. Don't you think there is a mutual agreement between parties like a quiet priod and signed non-disclosures between just the very top line??

All Peregrine needs is one....to step forward, as Stoxx1 has said.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote